Advertisement

InVivo Therapeutics today said that its previously announced $10.5 million private placement actually brought in $13 milion with additional units being purchased by Spencer Trask Ventures Inc., which served as placement agent and financial advisor.

InVivo, a Cambridge company working on a polymer-based treatment of spinal cord injuries, announced the private placement on Oct. 27, at the same time that it reported on a reverse merger conducted by InVivo Therapeutics Holdings Corp. (OTCBB: NVIV), a wholly owned subsidiary of that holding company.

SOURCE

Advertisement
Advertisement